Aducanumab Alzheimer antibody, illustration
Bildnummer 13443548
| Illustration showing Aducanumab (purple, lower left), a human-derived monoclonal immunoglobulin G (IgG) antibody binding to amyloid beta plaques (blue and yellow). Amyloid beta plaques are insoluble aggregates of amyloid beta protein. They are believed to be linked to Alzheimer's disease by causing nerve cell death and affecting nerve cell signalling pathways. Aducanumab binds to amyloid beta plaques by targeting an epitope found on the amyloid beta protein. This causes a reduction in beta amyloid plaques in the brain. Aducanumab could potentially slow down Alzheimer's disease progression, particularly patients in the earlier stages of the disease. On 7th of June 2021, Aducanumab was approved for treatment in Alzheimer's disease by the US Food and Drug Administration (FDA) through its accelerated approval pathway. | |
| Lizenzart: | Lizenzpflichtig |
| Credit: | Science Photo Library / Andrade, Ramon / 3dciencia |
| Bildgröße: | 3653 px × 4870 px |
| Modell-Rechte: | nicht erforderlich |
| Eigentums-Rechte: | nicht erforderlich |
| Restrictions: | - |
Preise für dieses Bild ab 15 €
Universitäten & Organisationen
(Informationsmaterial Digital, Informationsmaterial Print, Lehrmaterial Digital etc.)
ab 15 €
Redaktionell
(Bücher, Bücher: Sach- und Fachliteratur, Digitale Medien (redaktionell) etc.)
ab 30 €
Werbung
(Anzeigen, Aussenwerbung, Digitale Medien, Fernsehwerbung, Karten, Werbemittel, Zeitschriften etc.)
ab 55 €
Handelsprodukte
(bedruckte Textilie, Kalender, Postkarte, Grußkarte, Verpackung etc.)
ab 75 €
Pauschalpreise
Rechtepakete für die unbeschränkte Bildnutzung in Print oder Online
ab 495 €